News

New global data suggest children with moderate to severe atopic dermatitis may experience stunted growth due to the effect of their disease on sleep, as well as use of certain therapies.

Eiran Gorodeski, MD, MPH, discusses a recent scientific statement composed on behalf of the Heart Failure Society of America highlighting the impact of cognitive impairment on patients with heart failure.

Study links childhood amblyopia with increased risk of cardiometabolic dysfunction in adulthood.

Acadia Pharmaceuticals decided to stop conducting further clinical trials with pimavanserin for negative symptoms of negative due to topline results.

The phase 3 ENLIGHTEN program will consist of 2 phase 3 trials evaluating the safety and efficacy of pegozafermin in patients with MASH.

These data presented at AAD 2024 highlight deuruxolitinib’s efficacy in the treatment of adults with moderate-to-severe alopecia areata.

A greater patient-to-patient care technician ratio was associated with increased mortality and hospitalization with lower rates of waitlisting and transplantation among patients receiving in-center hemodialysis.

New data from the Mayo Clinic show high BMI does not correlate with severe hidradenitis suppurativa in affected children and adolescents.

Patients in France with hemophilia A who switched their FVIII replacement treatment trended towards fewer bleeding events and articular non-bleeding events requiring hospitalization.

This interview at AAD featured a discussion with Silverberg on nemolizumab’s efficacy and safety at Week 48 among patients with moderate-to-severe atopic dermatitis.

Blauvelt discusses the impetus for his phase 2 trial looking at the ability to mitigate pivotal psoriasis memory T cells with risankizumab.

Iron deficiency marks more than a comorbidity in heart failure, with adverse manifestations, including anemia and a higher risk of mortality, influencing the clinical trajectory of patients with HFrEF.

These study findings, presented at AAD 2024, were the results of a recent analysis conducted to assess long-term outcomes among patients with psoriasis.

In this segment of his AAD interview, Hamzavi discussed more about his team’s findings on upadacitinib as well as their implications and future in terms of research.

Baseline kidney function, AKD severity, and post-AKD kidney function were identified as important factors for predicting outcomes in patients with acute kidney injury requiring dialysis.

A new study found how premiums for lower-cost plans in Georgia did not reduce enough to make up for the decrease in subsidies, causing people in middle class to have to pay more.

A new study found older adults who are frail are less likely to engage in social interactions, which can cause them to lose social contact and create loneliness.

Nearly a decade after becoming the first PCSK9 inhibitor to receive approval from the FDA, alirocumab (Praluent) has now received approval for pediatric patients with HeFH based on data from a phase 3 trial.

Findings reveal a 20% mortality rate in an Eastern European cohort, primarily due to cardiovascular diseases and linked to an absence of RASi use, among other factors.

In a phase 3 trial that featured approximately half of participants with skin of color, tapinarof cream 1.0% provided consistent benefit for patients identified as White, Black, or Asian.

Kim discusses the state of dermatology innovation and applied care, as well as his involvement in a new company in the space.

In this interview segment, Lebwohl discusses the implications of his team’s late-breaking data on bimekizumab for clinical practice.

In this interview at AAD 2024, Porter discussed her team’s phase 2 findings on hidradenitis suppurativa the impact of ruxolitinib cream among those with Hurley Stage I and II.

Kimball discusses her team’s new late-breaking data regarding the safety and effectiveness of lutikizumab in treating the symptoms of moderate-to-severe HS in adult non-responders to anti-TNF therapy.

A secondary analysis from TRuE-AD3 shows ruxolitinib cream significantly benefits pediatric atopic dermatitis patient-reported outcomes.

This AAD 2024 interview features a discussion with Lebwohl on his team’s new late-breaking data, covering long-term findings on bimekizumab.

These phase 3 findings from AAD 2024 suggest patients treated with baricitinib may continue to see scalp, eyelash, and eyebrow hair regrowth with specific dosing regimens.

Thierry Passeron, MD, PhD, discusses the potential benefit of upadacitinib as an oral systemic therapy in patients with nonsegmental vitiligo.